

## Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction

Renda, Giulia; Pecen, Ladislav; Patti, Giuseppe; Ricci, Fabrizio; Kotecha, Dipak; Siller-Matula, Jolanta M; Schnabel, Renate B; Wachter, Rolf; Sellal, Jean-Marc; Rohla, Miklos; Lucerna, Markus; Huber, Kurt; Verheugt, Freek W A; Zamorano, Jose Luis; Brüggjenjürgen, Bernd; Darius, Harald; Duytschaever, Mattias; Le Heuzey, Jean-Yves; Schilling, Richard J; Kirchhof, Paulus

DOI:

[10.1007/s11739-020-02442-9](https://doi.org/10.1007/s11739-020-02442-9)

License:

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Renda, G, Pecen, L, Patti, G, Ricci, F, Kotecha, D, Siller-Matula, JM, Schnabel, RB, Wachter, R, Sellal, J-M, Rohla, M, Lucerna, M, Huber, K, Verheugt, FWA, Zamorano, JL, Brüggjenjürgen, B, Darius, H, Duytschaever, M, Le Heuzey, J-Y, Schilling, RJ, Kirchhof, P & De Caterina, R 2021, 'Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry', *Internal and emergency medicine*, vol. 16, no. 3, pp. 591-599. <https://doi.org/10.1007/s11739-020-02442-9>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Download date: 16. Sep. 2023



# Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry

Giulia Renda<sup>1</sup> · Ladislav Pecen<sup>2</sup> · Giuseppe Patti<sup>3</sup> · Fabrizio Ricci<sup>1</sup> · Dipak Kotecha<sup>4</sup> · Jolanta M. Siller-Matula<sup>5,6</sup> · Renate B. Schnabel<sup>7,8</sup> · Rolf Wachter<sup>9,22</sup> · Jean-Marc Sellal<sup>10</sup> · Miklos Rohla<sup>11</sup> · Markus Lucerna<sup>12</sup> · Kurt Huber<sup>13</sup> · Freek W. A. Verheugt<sup>14</sup> · Jose Luis Zamorano<sup>15</sup> · Bernd Brüggengjürgen<sup>16</sup> · Harald Darius<sup>17</sup> · Mattias Duytschaever<sup>18</sup> · Jean-Yves Le Heuzey<sup>19</sup> · Richard J. Schilling<sup>20</sup> · Paulus Kirchhof<sup>4</sup> · Raffaele De Caterina<sup>21</sup>

Received: 4 June 2020 / Accepted: 8 July 2020 / Published online: 21 September 2020  
© The Author(s) 2020

## Abstract

The management of patients with atrial fibrillation (AF) has rapidly changed with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs) and changes in the use of rhythm control therapy. The prevention of thromboembolic events European Registry in Atrial Fibrillation Prolongation Registry (PREFER Prolongation) enrolled consecutive patients with AF on NOACs between 2014 and 2016 in a multicentre, prospective, observational study with one-year follow-up, focusing on the time of introduction of NOACs. Overall, 3783 patients were enrolled, with follow-up information available in 3223 (85%). Mean age was  $72.2 \pm 9.4$  years, 40% were women, mean CHA<sub>2</sub>DS<sub>2</sub>VASc score was  $3.4 \pm 1.6$ , and 2587 (88.6%) had a CHA<sub>2</sub>DS<sub>2</sub>VASc score  $\geq 2$ . Rivaroxaban was used in half of patients, and dabigatran and apixaban were used in about a quarter of patients each; edoxaban was not available for use in Europe at the time. Major cardiovascular event rate was low: serious events occurred in 74 patients (84 events, 2%), including 24 strokes (1%), 62 major bleeds (2%), of which 30 were life-threatening (1%) and 3 intracranial (0.1%), and 28 acute coronary syndromes (1%). Mortality was 2%. Antiarrhythmic drugs were used in about 50% of patients, catheter ablation in 5%. Adverse events were low in this contemporary European cohort of unselected AF patients treated with NOACs already at the time of their first introduction, despite high thromboembolic risk.

**Keywords** Atrial fibrillation · Anticoagulants · NOAC · Registry · Major cardiac or cerebrovascular events · Bleeding

## Introduction

The non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used as an alternative to vitamin K antagonists (VKAs) to prevent strokes in patients with atrial fibrillation (AF) [1–4]. They include the direct thrombin inhibitor dabigatran, and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban. When compared with warfarin in

phase III randomized clinical trials [5–8], NOACs showed a consistently favourable benefit-risk profile across a wide range of patients, with lower mortality and a lower rate of intracranial haemorrhage than patients randomized to VKA [9, 10].

The aim of the PREFER in AF Prolongation study was to collect information on unselected patients with AF treated with NOACs at the beginning of their widespread introduction in Europe [11].

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s11739-020-02442-9>) contains supplementary material, which is available to authorized users.

✉ Raffaele De Caterina  
raffaele.decaterina@unipi.it

Extended author information available on the last page of the article

## Methods

PREFER in AF Prolongation was a multinational, multicentre, prospective, observational study with a baseline visit at the time of patient enrolment and a 1-year follow-up visit, with comparable data sets and methods to the prior PREFER in AF [12]. It was conducted in the same seven European countries as PREFER in AF registry, Austria, France, Germany, Italy, Spain, Switzerland, United Kingdom (UK), and in two additional countries, Belgium and the Netherlands. The baseline enrolment occurred between June 2014 and May 2015 and patients underwent follow-up visit after 1 year ( $12 \pm 1$  months, namely  $364 \pm 33$  days, after baseline visit); therefore, follow-up was concluded on June 2016, just before the publication of the current ESC guidelines on the management of AF [13].

Patients were included if they were at least 18 years of age, provided written informed consent for participation in the Registry, had a documented diagnosis of AF by ECG within the prior 12 months, and were treated with an oral anticoagulant. 10% of patients continued from PREFER in AF, of these around half were treated with VKAs and the remaining treated with NOACs. All newly enrolled patients reported in this analysis were treated with a NOAC, except edoxaban, that was not available for use in Europe at the time of PREFER in AF Prolongation registry. No explicit exclusion criteria were defined to encourage consecutive enrolment apart from patients with mechanical valve replacements or at least moderate mitral stenosis which were not eligible. Follow-up was performed one year after enrolment. Following types of clinical events were recorded during 1-year follow-up: ischemic stroke, transient ischemic attack (TIA), acute coronary syndrome, ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), unstable angina pectoris, stent insertion, coronary bypass surgery, chronic heart insufficiency, reduced left ventricular ejection fraction, arterial embolism, gastrointestinal bleeding, intracerebral bleeding, other life-threatening or major bleeding, venous thromboembolism event, and pulmonary thromboembolic event. Between these, major adverse cardiac and cerebrovascular events (MACCE) were evaluated. Data were captured through an electronic case report form (eCRF) including plausibility checks for the entered variables. The study management was overseen by a scientific steering committee, executed by a contract research organization (SSS International Clinical Research GmbH, Munich, Germany). The sponsor of the study was Daiichi-Sankyo Europe GmbH, Munich.

## Statistical analysis

All variables collected in the eCRF at baseline and follow-up, and all derived parameters were used in the statistical analysis. Statistical analysis was performed only on patients

with complete case data from baseline and follow-up visits, including those who died during the 1-year follow-up (for these patients we know the reason of death and information about drugs prescribed before death).

Binary, categorical, and ordinal parameters were summarized by means of absolute and percentage numbers within the various categories. Percentages were calculated from available results (there were few missing values, due to not entirely completed electronic case report forms). Numerical data were summarized by means of standard statistics (i.e., number of available data, number of missing data, mean, standard deviation, minimum, median, maximum, and lower and upper quartiles). Differences between follow-up and baseline data were evaluated by the Wilcoxon test for continuous variables and by the Chi-squared test for discrete variables. Mantel–Haenszel Chi-squared test was also used to assess the trend for categorical versus ordinal variables. Statistical significance was evaluated by a univariate logistic regression model. A two-tailed *p*-value of  $< 0.05$  was considered statistically significant.

The statistical analysis was performed using SAS v. 9.4 (SAS Institute Inc., Cary, USA).

## Results

### Patient characteristics and clinical presentation of atrial fibrillation

Overall, 3783 patients were enrolled into the PREFER in AF Prolongation registry. One-year follow-up was available in 3223 patients (85.2%). At enrolment, the mean age was  $72.2 \pm 9.4$  years, and 59.9% were male. Clinical characteristics of the population, including risk factors and comorbidities, are reported in Table 1. Compared with baseline, at follow-up, there were a higher number of patients with permanent AF (40.8% vs 31.4% at baseline,  $P < 0.0001$ ) and lower number with persistent AF (12.3% vs 23.6% at baseline,  $P < 0.0001$ ) (OS Fig. 1). At baseline, 2707 patients (84.1%) had symptomatic AF (defined by European Heart Rhythm Association, EHRA, score  $\geq$  II), and 2329 patients (74.1%) were symptomatic at follow-up ( $P < 0.0001$ ). Fatigue and dyspnoea were the most frequent symptoms; less frequent were palpitations, dizziness, chest pain, and anxiety. Severe symptoms, reflected by EHRA scores of III or IV, were less common at follow-up compared with baseline (EHRA IV = 10.1% vs 15.0%; III = 21.2% vs 28.0%;  $P < 0.0001$ ), while more patients had occasional symptoms or were asymptomatic at follow-up compared with baseline (EHRA II = 42.9% vs 41.2%; I = 25.9% vs 15.9%;  $P < 0.0001$ ). The mean EHRA score decreased from  $2.42 \pm 0.93$  at baseline to  $2.16 \pm 0.92$  at 1-year follow-up visit ( $P < 0.0001$ ).

**Table 1** Main clinical characteristics of the population ( $N=3223$ )


Age years, mean $\pm$ SD	72.2 $\pm$ 9.4
Female $n$ (%)	1292 (40.1)
Arterial hypertension $n$ (%)	2466 (76.7)
Diabetes mellitus (DM) $n$ (%)	745 (23.1)
Insulin therapy $n$ (%)	178 (24.0% of DM, 5.5% of pts)
Obesity (BMI > 30) $n$ (%)	933 (29.2)
Chronic obstructive pulmonary disease $n$ (%)	278 (8.6)
Current smoking $n$ (%)	221 (7.0)
Dyslipidaemia $n$ (%)	1310 (41.4)
Hyperthyroidism $n$ (%)	128 (4.0)
Chronic renal insufficiency $n$ (%)	630 (19.7)
Chronic hepatic disease $n$ (%)	31 (1.0)
Major previous GI/ cerebrovascular/other bleeding events $n$ (%)	121 (3.8)
Heart valve dysfunction $n$ (%)	1193 (37.3)
Heart valve replacement $n$ (%)	51 (4.3% of HVD, 1.6% of pts)
Type: biological valve $n$ (%)	49 (96.1% of HVR)
Coronary heart disease (CHD) $n$ (%)	648 (20.3)
Stent insertion $n$ (%)	345 (54.2% of CHD, 10.8% of pts)
Type: Bare-metal stent $n$ (%)	174 (52.7% of CHD)
Type: Drug-eluting stent $n$ (%)	156 (47.3% of CHD)
Previous MI $n$ (%)	279 (8.7)
Previous ischemic stroke $n$ (%)	383 (11.9)
Previous TIA $n$ (%)	326 (10.2)
Previous other ischemic-thromboembolic event $n$ (%)	196 (6.1)
Previous ischemic stroke/TIA/other ischemic-thromboembolic event $n$ (%)	530 (16.5)
Thromboembolic events $n$ (%)	87 (2.7)
Chronic heart insufficiency $n$ (%)	664 (20.7)
Reduced left ventricular ejection fraction $n$ (%)	432 (13.7)
Chronic heart insufficiency/reduced left ventricular ejection fraction $n$ (%)	799 (24.8)
Peripheral Arterial Disease (PAD) $n$ (%)	105 (3.3)
Prevalent cardiovascular disease (CHD, PAD, MI) $n$ (%)	696 (21.9)
HAS-BLED < 3 $n$ (%)	1942 (73.6)
Age > 65 $n$ (%)	2534 (78.6)
Age $\geq$ 75 $n$ (%)	1394 (43.3)
Uncontrolled hypertension (sBP > 160 mmHg) $n$ (%)	1251 (47.4)
Concomitant use of drugs (such as antiplatelet agents, NSAIDs) $n$ (%)	268 (8.4)
Excess alcohol use $n$ (%)	118 (3.7)

Percentages were calculated from the available results. *BMI* body mass index, *GI* gastrointestinal, *MI* myocardial infarction, *NSAIDs* nonsteroidal anti-inflammatory drugs, *TIA* transient ischemic attack

### Thromboembolic and bleeding risk

Thromboembolic risk, evaluated by  $CHA_2DS_2VASc$  score, was high at both baseline and follow-up (mean  $CHA_2DS_2VASc$ :  $3.36 \pm 1.57$  and  $3.40 \pm 1.56$ , respectively). The majority of patients had a  $CHA_2DS_2VASc$  score  $\geq 2$  (88.6% at baseline and 89.5% at follow-up). Modifiable and non-modifiable risk factors for bleeding (including concomitant use of drugs such as antiplatelet agents and nonsteroidal anti-inflammatory drugs, uncontrolled hypertension, excess alcohol use, chronic renal

insufficiency, chronic hepatic disease, age > 65 and  $\geq 75$ , history of previous stroke, history of major bleeding) are reported in Table 1. Particularly, antiplatelet drugs (mainly aspirin and/or clopidogrel) were used in 392 patients, (12%) in addition to NOAC at baseline [338 patient (10.5%) were also treated with a single antiplatelet agent and 54 patients (1.7%) with dual antiplatelet agents]. Combination therapy was, however, less frequent at follow-up [180 patients, 5.7%,  $P < 0.0001$ ; 155 patients (4.9%) were treated with one and 25 patients (0.79%) were treated with two antiplatelet agents] (see Table 2).



**Fig. 1** Frequency of NOAC prescription according to thromboembolic risk. Percentage of patients treated with apixaban (blue), dabigatran (yellow), and rivaroxaban (green) according to the CHA<sub>2</sub>DS<sub>2</sub>VASc score. Patient number for each category is reported in brackets

**Stroke prevention therapy**


Rivaroxaban was used by 1667 patients (52%) treated with NOACs, compared with dabigatran and apixaban, which were used by 797 (25%) and 842 (26%) patients, respectively, with minimal variations between baseline and follow-up visit (Table 2); in 83 patients (3%), two types of NOAC were reported at baseline (usually intake of one of them was stopped shortly after baseline visit).

The different distribution of NOAC use in the nine European countries was reported in OS Table 1. Out of 3223 patients, 5 (0.16%) discontinued a NOAC; 117 patients (3.6%) switched from one NOAC to another during the 1-year follow-up (OS Fig. 2); 29 patients (25% of switchers) switched to rivaroxaban (mainly from dabigatran); 68 patients (58%) switched to apixaban (mainly from rivaroxaban); and 20 patients (17%) switched to dabigatran (mainly from rivaroxaban); 48 patients (6.0%) treated with dabigatran, 55 (3.3%) treated with rivaroxaban and 14 (1.7%) treated with apixaban switched to another NOAC ( $p=0.0617$ ; OS Fig. 2). The reasons given for switching in these 117 patients were adverse drug reaction (26 patients, 22.2%), inconvenience/non-compliance (20 patients, 17.1%), lack of efficacy (mainly related to the occurrence of cardiovascular events in 13 patients, 11.1%), drug-drug interaction (6 patients, 5.1%), minor surgery (5 patients, 4.3%) and high variability of response (2 patients, 1.7%). Drug changes occurred without a documented reason in 76 patients (65%), and 31 patients (1%) had more than one reason.

**Table 2** Distribution of NOACs, alone or in combination with antiplatelets, at baseline and follow-up

Drug	Baseline n (%)	Follow-up* n (%)	Follow-up vs baseline P
NOACs	3223 (100.0)	3149 (100.0)	NA
NOACs monotherapy	2831 (87.84)	2969 (94.28)	<0.0001
NOACs + antiplatelets	392 (12.16)	180 (5.72)	<0.0001
<i>Type of NOAC</i>			
Dabigatran	797 (24.73)	738 (23.44)	0.2277
Rivaroxaban	1667 (51.72)	1613 (51.22)	0.6901
Apixaban	842 (26.12)	879 (27.91)	0.1078
<i>Type of antiplatelet</i>			
Aspirin	327 (10.15)	142 (4.51)	<0.0001
Clopidogrel	104 (3.23)	58 (1.84)	0.0004
Prasugrel	4 (0.12)	1 (0.03)	0.1881
Ticagrelor	2 (0.06)	3 (0.10)	0.6359
Single antiplatelet therapy	338 (10.5)	155 (4.9)	<0.0001
Double antiplatelet therapy	54 (1.67)	25 (0.79)	0.0015

\*Patients who died and were withdrawn from NOACs during 1-year FU were excluded from the FU column. Statistically significant P values are in bold



**Fig. 2** Cumulative proportion of MACCE during the observation period. Panel A shows full analysis set. Panel B shows the incidence of MACCE according to the CHA<sub>2</sub>DS<sub>2</sub>VASc score  $\geq 2$  (green line) vs 0 or 1 (red line)



Apixaban was used slightly more often with increasing  $\text{CHA}_2\text{DS}_2\text{VASc}$  score ( $P=0.0004$ ); while dabigatran was prescribed nominally less often with increasing  $\text{CHA}_2\text{DS}_2\text{VASc}$  score ( $P=0.0389$ ) (Fig. 1). There was no detectable correlation between  $\text{CHA}_2\text{DS}_2\text{VASc}$  score and rivaroxaban prescription ( $P=0.2165$ ) (Fig. 1). Similar associations were observed with increasing HAS-BLED scores (data not shown).

### Clinical events


A total of 468 clinical events occurred in 348 patients (10.8%) between baseline and follow-up: of these, 24 were strokes (0.8%), 62 (2.0%) major bleeding of which three were intracerebral bleeding (0.1%) and 37 other life-threatening bleeding events (1.2%), 28 were acute coronary syndromes (0.9%) and 2 (0.1%) were arterial embolisms (OS Table 2 shows the main clinical events that occurred between baseline and follow-up). No significant difference ( $P=0.1922$ ) was found in major bleeding between patients not treated with antiplatelet drugs (1.8%) and patients treated with one (3.04%;  $\text{HR}=1.71$ , 95%  $\text{CI}=0.86\text{--}3.40$ ) or two antiplatelet agents (3.85%;  $\text{HR}=2.18$ , 95%  $\text{CI}=0.52\text{--}9.20$ ).

Mortality was 2.1% (69 deaths were reported out of 3223 patients); cardiovascular (CV)-related death comprised 40 (58.0%) of all deaths (1.2% of all patients). The most common fatal event was unspecified cardiovascular death (20 deaths), followed by death due to heart failure (10 deaths) and cancer (8 deaths) (OS Table 3). A total of 84 major adverse cardiac and cerebrovascular events (MACCE) occurred in 74 patients (2.3%; Fig. 2a): in addition to the strokes and life-threatening bleeding, they included 28 acute coronary syndromes (0.9%).

Overall, the incidence of MACCE appeared higher in patients with a  $\text{CHA}_2\text{DS}_2\text{VASc}$  score  $\geq 2$  (2.5%) compared with patients with a score of 0 or 1 (0.9%;  $P=0.0672$ ), although there was no difference in MACCE incidence between  $\text{CHA}_2\text{DS}_2\text{VASc}$  0–1 vs  $\geq 2$  during first 6 months (Fig. 2b). The highest incidence of MACCE is for a  $\text{CHA}_2\text{DS}_2\text{VASc}$  score = 7, followed by a  $\text{CHA}_2\text{DS}_2\text{VASc}$  score = 6. There are a very low number of patients with  $\text{CHA}_2\text{DS}_2\text{VASc}$  8–9, and no MACCE events (OS Table 4). Figure 3 shows the incidence of MACCE according to  $\text{CHA}_2\text{DS}_2\text{VASc}$  category.  $\text{CHA}_2\text{DS}_2\text{VASc}$  score was different between patients with and without events ( $3.74 \pm 1.51$  with MACCE vs.  $3.33 \pm 1.56$  without MACCE,  $p=0.0361$ ).

### Rate and rhythm control therapy

Control of heart rate, as assessed by the resting ECG, was generally good, both for asymptomatic and symptomatic patients; more patients had adequate rate control (heart rate 60–100/min) at follow-up compared with baseline (81.8%



**Fig. 3**  $\text{CHA}_2\text{DS}_2\text{VASc}$  score in patients presenting MACCE compared with those not presenting. Error bars show standard deviation

versus 78.4%;  $P=0.0009$ ). Rhythm control procedures, i.e. cardioversion, pharmacological or electrical cardioversion or AF ablation, were performed in 356 patients (11.3%) during follow-up, more often used in the year before enrolment than in the year after enrolment (OS Table 5). No relationship was observed between the type of NOAC and cardioversion or ablation (data not shown). Antiarrhythmic drugs at baseline were used in 1597 (49.6%). The most commonly used antiarrhythmic drug was amiodarone (16.3% of patients), followed by flecainide 9.7%, sotalol 5.0%, propafenone 1.4%, dronedarone 1.2% and quinidine 0.6%; 15.4% of patients were treated with other antiarrhythmic, not specified, drugs. At the follow-up visit, antiarrhythmic drugs were used in 43.1% of patients (1391 patients;  $P<0.0001$  vs baseline); again, amiodarone was the most used drug (13.4% of patients), followed by flecainide (9.2%), sotalol (5.1%), dronedarone (1.0%), propafenone (0.9%) and quinidine (0.4%); 13.1% of patients were treated with other antiarrhythmic, not specified, drugs.

### Discussion

The PREFER in AF Prolongation study provides valuable information on the characteristics and outcomes of patients treated with NOACs in Europe in 2014 and 2015, coinciding with the time of introduction of these at that time novel drugs in the therapeutic armamentarium. Patient characteristics (mean age 72.5 years, 60% male) were comparable with those of PREFER in AF [12] and other registries [14–16]; therefore, this cohort can be considered representative for the management of AF at that time. Thromboembolic risk was high, as expected in a cohort of anticoagulated patients

with AF, and comparable to the phase III trials [5–8] and to other AF registries [12, 14–16]. This is notable as initial reports of the use of NOACs found that they were often in “low-risk” patients. Bleeding risk as estimated by HAS-BLED score was relatively low, and lower at 1-year follow-up, reflecting less unnecessary antiplatelet treatment [17] and potentially reduction of other modifiable bleeding risk factors. Importantly, the use of combination therapy with NOACs plus antiplatelets decreased by half from baseline to follow-up, this is probably explained by the interruption of a dual antiplatelet therapy started prior to enrolment and completed after prescribed period, or to a higher attention to guideline indications, particularly in combination therapy, sometimes inappropriately used in stable coronary artery disease<sup>17</sup>. Rivaroxaban was prescribed in half of the patients, while dabigatran and apixaban were used in about a quarter of patients, respectively. Since edoxaban was not available for use in Europe at the time of enrolment in the PREFER in AF Prolongation registry, we have no data about this drug in this registry. The incidence of switching from one NOAC to another was low (3.6%) during the 1-year follow-up, without a clear pattern between the different agents. Voluntary switch was the main reason for changing.

Stroke rate (24 events, 0.8%) and major cardiovascular event rate (2.3%, 84 events in 74 patients) were low and seemed related to thromboembolic risk factors. MACCE rate was nominally lower than that observed in PREFER in AF, enrolled in a similar registry only 2 years earlier (237 events in 217 patients, 3.4%) [12]. This may reflect a slightly lower risk of the population enrolled in the PREFER in AF Prolongation compared with that enrolled in PREFER in AF. Most likely, the lower rate of events was due to a different anticoagulant treatment: all patients newly enrolled in the PREFER in AF Prolongation were treated with a NOAC, while only 6% of patients enrolled in PREFER in AF were treated with a NOAC, 77% were treated with a VKA and the others with antiplatelet agents or no antithrombotic drug.

Accordingly, mortality was low (2.1%), and CV-related mortality was 57.5% of the total mortality. Although the overall incidence of MACCE appeared higher in patients with a CHA<sub>2</sub>DS<sub>2</sub>VASc score  $\geq 2$  compared with patients with a score of 0 or 1 at 1-year follow-up, this difference became more evident after 6 months, probably due to the absence of events in patients with CHA<sub>2</sub>DS<sub>2</sub>VASc 0–1 in this period. Overall, the registry demonstrates, in a real-life setting, the low rates of thromboembolic and bleeding events occurring in well-treated patients with AF. This is in agreement with data from other real-life studies, overall reporting a lower incidence of adverse events compared with randomized clinical trial. The rate of events may be different between registries due to different inclusion criteria, study design, period of data collection, duration of follow-up, regional contribution and participating physicians.

The proportion of patients with permanent AF increased during follow-up, reflecting the progressive nature of AF. The use of rhythm control therapy, mainly antiarrhythmic drugs, but also AF ablation, was lower compared to other reports [18], and decreased from baseline to follow-up. At the same time, patients were less symptomatic at follow-up than at baseline, illustrating the changing nature of symptoms in patients with atrial fibrillation, probably reflecting the higher number of patients with permanent AF.

## Study limitations

This analysis from the PREFER in AF Prolongation registry provides a snapshot of AF patients treated with NOACs in nine European countries, and the follow-up data shows the one-year evolution compared with baseline. However, about 15% of patients were lost to follow-up, and information about events that occurred the year before baseline and during follow-up was not always complete. Therefore, statistical analysis was performed only on patients with complete case data from baseline and follow-up visits, including dead patients which data were completely recorded.

Inherent to other similar registries, selection bias cannot be ruled out at the centre or patient level. Moreover, here we considered only patients treated with NOACs, but we could not obtain either information about previous anticoagulant treatment (time of NOAC initiation or time of switching from VKAs) or about the dosages of each drug. Finally, due to the observational nature of the study, the effects of different NOACs could not be compared.

## Conclusions

This registry of European patients at the beginning of the NOAC era found low event rates in AF patients treated with NOACs, despite high thromboembolic risk. This provides reassurance regarding the use of these agents in “real-life” conditions already at the beginning of the NOAC era. Treatment patterns had already changed compared to earlier reports, including a lower use of combination therapy with antiplatelet agents, and the improved management of modifiable bleeding risk factors over time, reflecting the rapidly shifting reality of AF management with the introduction of the NOACs.

**Author contributions** All authors contributed to the data analysis and interpretation. GR wrote the first draft. PK and RDC made the revision of the final document. All authors consented to publishing the present report.

**Funding** Open access funding provided by Università di Pisa within the CRUI-CARE Agreement. The PREFER in AF Prolongation registry was sponsored by Daiichi-Sankyo Europe GmbH. The members of the steering committee received honoraria for their advice in the planning of the registry.

## Compliance with ethical standards

**Conflict of interest** GR: speaker and consultancy fees from Bayer, BMS/Pfizer, Boehringer-Ingelheim, and Daiichi-Sankyo; LP: consultancy fees from Daiichi-Sankyo, SOTIO, Roche Diagnostics and Beckman-Coulter; GP: speaker/consultant/advisory board member for Amgen, Astra Zeneca, Bayer, BMS-Pfizer, Boehringer-Ingelheim, Daiichi-Sankyo, Malesci, MSD, PIAM, Sanofi and Sigma-Tau; FR: no disclosure; DK: grants from Menarini outside the submitted work but during the conduct of the study and professional development support from Daiichi-Sankyo; JMSM: lecture or consultant fees from AstraZeneca, Daiichi-Sankyo, Eli Lilly, Bayer and research grant from Roche Diagnostics; RBS: funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 648131), German Ministry of Research and Education (BMBF 01ZX1408A) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103); RW: speaker or consultant for Bayer, BMS, Boehringer-Ingelheim, CVRx, Medtronic, Novartis, Pfizer, Sanofi, Servier; research support from Boehringer-Ingelheim, Bundesministerium für Bildung und Forschung and European Union; JMS: speaker and consultancy fees from Boehringer-Ingelheim, Bayer and BMS-Pfizer; MR: advisory fees from Daiichi-Sankyo and Novartis and lecturing fees from Biotronik and Takeda Pharma, all outside of the submitted work; ML: employee of Daiichi-Sankyo Europe. KH: lecture fees from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb/Pfizer, and Daiichi-Sankyo; FWAV: personal fees from Boehringer-Ingelheim, Bayer AG, BMS/Pfizer, Daiichi-Sankyo and AstraZeneca; JLZ: speaker honoraria from Sanofi, Servier and Daiichi-Sankyo; BB: consultant for Daiichi-Sankyo. HD: Steering Committee member and National Coordinator for Germany RE-LY, APPRAISE- 1 and 2, Garfield Registry, and PREFER in AF; fees, honoraria, and research funding from AstraZeneca, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi-Sankyo, Lilly, MSD Sharp&Dohme, BMFT, Harvard Med. Res. Inst., and Thrombosis Research Institute; MD: grants for investigator-initiated studies and related travel expenses from Biosense Webster, Medtronic, St Jude Medical and Boston Scientific; J-YLH: consultant/conferences/advisory board for Sanofi-Aventis, BMS/Pfizer, Meda, Boehringer-Ingelheim, MSD, Bayer, Servier and Daiichi-Sankyo; RJS: research funding from Biosense Webster, Medtronic, St. Jude Medical, Hansen Medical, and Boston Scientific; PK: research support from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation; honoraria from several such companies; PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783); RDC: grant support (to his institution) from Boehringer-Ingelheim, Bayer, BMS/Pfizer, and Daiichi-Sankyo; speaker and consultancy fees from Boehringer-Ingelheim, Bayer, BMS/Pfizer, Daiichi-Sankyo, Merck, Novartis, Roche, Portola.

**Availability of data and material (data transparency)** To be negotiated with the Sponsor and the Steering Committee.

**Human and animal rights** All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the 1964

Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent** All participants provided informed consent prior to their participation

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References


1. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK (2017) Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. *Heart* 103:307–314
2. Loo SY, Dell'Aniello S, Huiart L, Renoux C (2017) Trends in the prescription of novel oral anticoagulants in UK primary care. *Br J Clin Pharmacol* 83:2096–2106
3. Morgan A, Joshy G, Schaffer A, Laba TL, Litchfield M, Pearson S, Banks E (2018) Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants. *PLoS One* 13:e0208824
4. van den Heuvel JM, Hövels AM, Büller HR, Mantel-Teeuwisse AK, de Boer A (2018) Maitland-van der Zee AH. NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands. *Thrombosis J* 16:7
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 361:1139–1151
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 365:883–891
7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 365:981–992
8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 369:2093–2104



9. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI (2012) New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. *J Am Coll Cardiol* 59:1413–1425
10. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 383:955–962
11. Kirchhof P (2017) The future of atrial fibrillation management: integrated care and stratified therapy. *Lancet* 390:1873–1887
12. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, Zamorano JL (2014) Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic events–European Registry in Atrial Fibrillation (PREFER in AF). *Europace* 16:6–14
13. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P (2016) ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 37:2893–2962
14. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Verheugt FW, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AG (2012) International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). *Am Heart J* 163:13–19.e11
15. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijs HJ, Simantirakis E, Atar D, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP (2014) A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. *Europace* 16:308–319
16. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma C, Zint K, Elsaesser A, Bartels DB, Lip GY (2015) Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. *Am J Med* 128:1306–1313.e1301
17. De Caterina R, Ammentorp B, Darius H, Le Heuzey JY, Renda G, Schilling RJ, Schliephacke T, Reimitz PE, Schmitt J, Schober C, Zamorano JL, Kirchhof P (2014) Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. *Heart* 100:1625–1635
18. Schnabel RB, Pecun L, Ojeda FM, Lucerna M, Rzayeva N, Blankenberg S, Darius H, Kotecha D, Caterina R, Kirchhof P (2017) Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. *Heart* 103:1024–1030

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Affiliations

Giulia Renda<sup>1</sup> · Ladislav Pecen<sup>2</sup> · Giuseppe Patti<sup>3</sup> · Fabrizio Ricci<sup>1</sup> · Dipak Kotecha<sup>4</sup> · Jolanta M. Siller-Matula<sup>5,6</sup> · Renate B. Schnabel<sup>7,8</sup> · Rolf Wachter<sup>9,22</sup> · Jean-Marc Sellal<sup>10</sup> · Miklos Rohla<sup>11</sup> · Markus Lucerna<sup>12</sup> · Kurt Huber<sup>13</sup> · Frek W. A. Verheugt<sup>14</sup> · Jose Luis Zamorano<sup>15</sup> · Bernd Brüggengjürgen<sup>16</sup> · Harald Darius<sup>17</sup> · Mattias Duytschaever<sup>18</sup> · Jean-Yves Le Heuzey<sup>19</sup> · Richard J. Schilling<sup>20</sup> · Paulus Kirchhof<sup>4</sup> · Raffaele De Caterina<sup>21</sup> 

<sup>1</sup> Department of Neuroscience, Imaging, and Clinical Science, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy

<sup>2</sup> Institute of Computer Science, Academy of Sciences of the Czech Republic, Prague, Czech Republic

<sup>3</sup> Department of Translational Medicine, University of Eastern Piedmont and Maggiore Della Carità Hospital, Novara, Italy

<sup>4</sup> University of Birmingham Institute of Cardiovascular Sciences, and UHB and SWBH NHS Trusts, Birmingham, UK

<sup>5</sup> Department of Cardiology, Medical University of Vienna, Vienna, Austria

<sup>6</sup> First Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland

<sup>7</sup> Department for General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany

<sup>8</sup> German Center for Cardiovascular Research (DZHK) Partner Site Hamburg / Kiel/ Lübeck, Hamburg, Germany

<sup>9</sup> Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany

<sup>10</sup> Department of Cardiology, University Hospital of Nancy, Nancy, France

<sup>11</sup> Third Medical Department, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, Vienna, Austria

<sup>12</sup> Daiichi-Sankyo Europe, Munich, Germany

<sup>13</sup> Third Medical Department, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, and Sigmund Freud University, Medical School, Vienna, Austria

<sup>14</sup> Emeritus Professor of Cardiology, Amsterdam, The Netherlands

<sup>15</sup> Department of Cardiology, University Hospital Ramo N Y Cajal, Madrid, Spain

<sup>16</sup> Institute for Health Economics, Steinbeis-University, Berlin, Germany

<sup>17</sup> Vivantes Hospital Neukölln, Berlin, Germany

<sup>18</sup> Department of Cardiology, Sint-Jan Hospital Bruges, Bruges, Belgium

<sup>19</sup> Georges Pompidou Hospital-René Descartes University, Paris, France

<sup>20</sup> London Bridge Hospital, London, UK

<sup>21</sup> Chair of Cardiology, University Cardiology Division, University of Pisa, Pisa University Hospital, Pisa, and Fondazione VillaSerena Per La Ricerca, Città Sant'Angelo, Pescara, Italy

<sup>22</sup> DZHK (German Centre for Cardiovascular Research), Partner site, Göttingen, Germany